Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| Enclomiphene | Testosterone Enanthate | |
|---|---|---|
| Category | Hormones | Hormones |
| Standard Dose | Research indicates 12.5-25 mg daily orally for testosterone restoration in secondary hypogonadism. | Research indicates 100-200 mg administered via intramuscular or subcutaneous injection every 7-14 days for testosterone replacement. |
| Timing | Once daily, morning preferred. No food timing requirements. Consistent daily dosing for optimal HPG axis stimulation. | Consistent injection schedule. Twice-weekly splits provide more stable blood levels due to the slightly shorter half-life compared to cypionate. |
| Cycle Duration | Long-term use (months to years) is feasible due to absence of zuclomiphene accumulation issues. Reassess every 3-6 months. | Ongoing for TRT. Suppression of endogenous production is expected within weeks of initiation. |
| Evidence Level | moderate_human | strong_human |
Enclomiphene is the purified trans-isomer of clomiphene citrate that acts as a selective estrogen receptor antagonist at the hypothalamus and pituitary without the estrogenic agonist activity of the zuclomiphene isomer. By blocking estrogen receptor alpha (ERa) in the hypothalamus, it removes estradiol-mediated negative feedback on GnRH neurons, resulting in increased pulsatile GnRH release and consequent elevation of LH and FSH from the anterior pituitary. This stimulates endogenous Leydig cell testosterone production while preserving spermatogenesis — a critical advantage over exogenous testosterone.
Research indicates 12.5-25 mg daily orally for testosterone restoration in secondary hypogonadism.
Once daily, morning preferred. No food timing requirements. Consistent daily dosing for optimal HPG axis stimulation.
Long-term use (months to years) is feasible due to absence of zuclomiphene accumulation issues. Reassess every 3-6 months.
Testosterone enanthate is a long-acting esterified testosterone prodrug with a heptanoic acid ester at the 17-beta hydroxyl group, extending its half-life to approximately 4.5-5 days. Upon hydrolysis by tissue esterases, free testosterone activates nuclear androgen receptors, upregulating anabolic gene transcription including myostatin suppression and IGF-1 induction. It also modulates the hypothalamic-pituitary-gonadal (HPG) axis via negative feedback on GnRH and LH secretion.
Research indicates 100-200 mg administered via intramuscular or subcutaneous injection every 7-14 days for testosterone replacement.
Consistent injection schedule. Twice-weekly splits provide more stable blood levels due to the slightly shorter half-life compared to cypionate.
Ongoing for TRT. Suppression of endogenous production is expected within weeks of initiation.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →